Correlation of serum 25-(OH)D,miR-26a,and CTRP3 levels with CIMT and CVD risk in patients with type 2 DM
O4bjective To investigate the correlation between serum 25-hydroxy vitamin D(25-(OH)D),microRNA(miR)-26a,and complement C1q/tumor necrosis factor-related protein 3(CTRP3)lev-els and carotid intima-media thickness(CIMT)and cardiovascular disease(CVD)risk in patients with type 2 diabetes.Methods A total of 112 patients with type 2 diabetes admitted to the Sixth People's Hospital of Nan-tong between June 2022 and June 2024 were selected as the study subjects.They were divided into three groups based on their risk class of cardiovascular disease:a low-risk group(28 patients),an intermediate-risk group(39 patients),and a high-risk group(45 patients).Differences in serum 25-(OH)D,miR-26a,and CTRP3 levels were compared among the 3 groups.The correlation between the above indicators and the risk of CIMT and CVD in patients with type 2 diabetes mellitus was analyzed using Spearman correlation analysis and multi-variate logistic regression.Results Compared to the gender of the 3 groups,the difference was not statisti-cally significant(P>0.05).when comparing the age and CIMT in the 3 groups,there was a statistically signifi-cant difference,with the low-risk group<intermediate-risk group<high-risk group(P<0.05).The comparison of serum 25-(OH)D,miR-26a,and CTRP3 levels among the 3 groups showed that the low-risk group>inter-mediate-risk group>high-risk group,and the differences were statistically significant(P<0.05).The results of Spearman correlation analysis and multivariate logistic regression analysis indicated that serum 25-(OH)D,miR-26a,and CTRP3 levels were all negatively correlated with the risk of CIMT and CVD in patients with type 2 diabetes mellitus,and the differences were statistically significant(P<0.05).Conclusion Serum 25-(OH)D,miR-26a,and CTRP3 levels are correlated with CIMT and CVD risk in patients with type 2 diabetes mellitus.They can be used as auxiliary indicators to clinically suggest the occurrence of cardiovascular disease in patients with type 2 diabetes mellitus.